After search, choose a molecule or a kind of categories listed in the left to narrow down your filter. If you have any problems, please contact us!
Text Size:AAA

vWF Antibody, Mouse MAb

DatasheetSpecific ReferencesReviewsRelated ProductsProtocols
Human vWF Antibody Product Information
Immunogen:CHO cell-derived rhvWF (Catalog#10973-H08C)
Clone ID:7G2B11C10
Ig Type:Mouse IgG2a
Formulation:0.2 μm filtered solution in PBS with 5% trehalose
Preparation:This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human von Willebrand factor (rhvWF; Catalog#10973-H08C; aa 1-2813; NP_000543.2). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Human vWF Antibody Usage Guide
Specificity:Human vWF
Application:ELISA, IHC-P

ELISA: 0.25-0.5 μg/mL

This antibody can be used at 0.25-0.5 μg/mL with the appropriate secondary reagents to detect vWF. The detection limit for vWF is approximately 10 ng/well.

IHC-P: 1-5 μg/mL

Storage:This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Other vWF Antibody Products
VWF Background

Von Willebrand Factor (VWF) is a multimeric glycoprotein involved in hemostasis in blood, binds receptors on the surface of platelets and in connective tissue, thereby mediating the adhesion of platelets to sites of vascular injury. From studies it appears that VWF protein uncoils under these circumstances, decelerating passing platelets. VWF protein is deficient or defective in von Willebrand disease (VWD) and is involved in a large number of other diseases, including thrombosis, thrombotic thrombocytopenic purpura, Stroke, Heyde's syndrome, possibly hemolytic-uremic syndrome and so on.

Human VWF References
  • Sadler JE. (1998) Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem, 67: 395-424.
  • Batlle J, et al. (2009) Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Blood Coagul Fibrinolysis. 20(2):89-100.
  • Sadler JE. (2009) von Willebrand factor assembly and secretion. J Thromb Haemost. 7 Suppl 1:24-7.
  • Auton M, et al. (2010) The mechanism of VWF-mediated platelet GPIbalpha binding. Biophys J. 99(4):1192-201.
  • Bowen DJ. (2010) Sugar targets VWF for the chop. Blood. 115(13):2565.
  • Lpez JA, et al. (2010) VWF self-association: more bands for the buck. Blood. 116(19):3693-4.
  • Product nameProduct name